The primary objective of this research was to identifyand explorethe most potent and efficacious cyclooxygenase inhibitors, utilizingindole acetic acid drugs as a lead molecule. To achieve this objective,various derivatives (2a-2c and 2e-2g) of the selected lead molecule, indomethacin, were synthesized usinga reflux condensation process, targeting the hydroxyl group. The synthesizedanalogues were subjected to different spectroscopic procedures todetermine their structure and confirm their analogues. These derivativeswere further screened for acute toxicity and anti-nociceptive andanti-inflammatory activity using established protocols. Docking analysiswas performed to evaluate the possible protein-ligand interaction.The test compounds were found to be safe at doses of 50, 75, 100,and 200 mg/kg, i.p. The pharmacological screening revealed that testcompounds 2a-2f had a superior peripheral analgesiceffect at a dose of 10 mg/kg, in comparison to the parent drug indomethacin,while compound 2g exhibited slightly lower activity atthe same dose. The hot plate results showed lower central analgesicactivity of the test compounds compared to the standard Tramal, butit was still significant. Anti-inflammatory results were significant,comparable to Diclofenac sodium and indomethacin, except for compounds 2b, 2c, and 2e at a dose of 10 mg/kgbody weight. Molecular docking analysis demonstrated that the derivedcompounds had augmented negative binding energies (-149.39,-146.72, -160.85, -159.34, -140.03, and-150.91 KJ/mol) compared to the parent drugs (-141.07),which supported the research's theme of producing strongerderivatives of standard drugs with significant anti-nociceptive andanti-inflammatory potential. The derived compounds exhibited significantanalgesic and anti-inflammatory activities and, therefore, have thepotential to be studied further as new drug candidates for pain andinflammation.